Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.

Biotecnología

Ms. Justine  O'Malley

Senior Vice President of Investor Relations & Corporation Affairs

Ms. Mary J. Grendell

Gen. Counsel & Corporation Sec.

Dr. Jacqueline  Zummo M.B.A., M.P.H., Ph.D.

Co-Founder, Senior Vice President & Chief Scientific Operations Officer

Ms. Kristine  Rosse

Senior Vice President & Chief People Officer

Dr. Jathin  Bandari M.D.

Chief Medical Officer

Mr. Patrick  Fabbio M.B.A.

Chief Financial Officer

Ms. Hannah  Fry

Vice President, Principal Accounting Officer & Controller

Mr. Jesse  Shefferman

Co-Founder, Chief Executive Officer, Pres & Director

Principal Accounting Officer & Controller

Co-Founder, Principal Financial Officer, Chief Executive Officer, Pres & Director

Nombre	Capitalización
hVIVO plc	0M
VistaGen Therapeutics, Inc.	0M
Exopharm Limited	0M
Yunnan Botanee Bio-Technology Group Co.LTD	0M
BioVaxys Technology Corp.	0M
MedMira Inc.	0M
Regenicin, Inc.	0M
Vascular Biogenics Ltd.	0M
CorMedix Inc.	0M
Wave Life Sciences Ltd.	0M

Protara Therapeutics, Inc.

Protara Therapeutics, Inc. Lista de competidores

Principales competidores